drugset / Trial / NCT07138898

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898

Phase 2 Recruiting 80 enrolled NYU Langone Health
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

Timeline

Start
2025-12-12
Primary completion
2028-01
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified
Subject Adalimumab Monoclonal antibody
Subject Anakinra Protein / enzyme biologic
Subject Azathioprine Small molecule
Subject Belimumab Monoclonal antibody
Subject Bimekizumab Monoclonal antibody
Subject Canakinumab Monoclonal antibody
Subject Certolizumab Protein / enzyme biologic
Subject Cyclosporine Peptide
Subject Etanercept Protein / enzyme biologic
Subject Golimumab Monoclonal antibody
Subject Guselkumab Monoclonal antibody
Subject Hydroxychloroquine Small molecule
Subject Infliximab Monoclonal antibody
Subject Ixekizumab Monoclonal antibody
Subject Leflunomide Small molecule
Subject Methotrexate Small molecule
Subject Mycophenolate Sodium Unknown
Subject Risankizumab Monoclonal antibody
Subject Rituximab Monoclonal antibody
Subject Secukinumab Monoclonal antibody
Subject Sulfasalazine Small molecule
Subject Tacrolimus Small molecule
Subject Tocilizumab Monoclonal antibody
Subject Tofacitinib Small molecule
Subject Upadacitinib Small molecule
Subject Ustekinumab Monoclonal antibody

Indications